Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Transplantation|June 4, 2011
Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcomeMichelle Willicombe, Candice Roufosse, Paul Brookes, et al.Kidney International|September 16, 2011
Mice with defective Fas ligand are protected from crescentic glomerulonephritisRuth M Tarzi, Phoebe E H Sharp, John P McDaid, et al.Transplantation|January 20, 2012
Advising potential recipients on the use of organs from donors with primary central nervous system tumorsAnthony N Warrens, Rhiannon Birch, David Collett, et al.Oncogene|June 10, 2014
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cellsMark H Tuthill, Antonella Montinaro, Julia Zinngrebe, et al.Transplantation|October 15, 2008
ABO incompatible living renal transplantation with a steroid sparing protocolJack Galliford, Rawya Charif, Ka Kit Chan, et al.Transplantation|August 13, 2011
Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trialKakit Chan, David Taube, Candice Roufosse, et al.Transplantation|May 22, 2018
Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic ReviewBénédicte Sautenet, Allison Tong, Jeremy R Chapman, et al.Clinical Genitourinary Cancer|January 17, 2018
Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional CenterHelen E J Tyrrell, David N Church, Johnson Joseph, et al.European Journal of Immunology|November 10, 2010
Analysis of the peripheral T-cell repertoire in kidney transplant patientsPatrick Miqueu, Nicolas Degauque, Marina Guillet, et al.Transplantation Direct|August 9, 2016
Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney TransplantationAllison Tong, Klemens Budde, John Gill, et al.Pageof 5